JFK Advanced Lung and Airway Center Pioneers Novel Procedure To Help Patients with Advanced Emphysema
What You Need To Know
JFK University Medical Center’s Advanced Lung and Airway Center now offers a new lung valve treatment for patients with severe COPD and emphysema. Zephyr® Valves received breakthrough device designation and were approved by the FDA in 2018. The Zephyr Valve treatment helps patients breathe easier and do more without many of the risks associated with major surgery. What makes the program at the JFKUMC Advanced Lung and Airway Center unique is our robotic technique to separate fused fissures and then place the valve during the same surgery in patients who would not otherwise be candidates.
More than 15 million Americans suffer from COPD, and 3.5 million of those patients have emphysema.2 Emphysema is a progressive and life-threatening lung disease, and a severe form of COPD (chronic pulmonary obstructive disease).
Pulmonologists, who specialize in expert treatment of diseases of the lung, play an important role in treating patients with COPD and referring them for specialized treatment such as the Zephyr valves when their lung disease worsens.
Despite routine pulmonary care, there is no cure for COPD and patients live with severe shortness of breath that keeps them from doing simple daily activities like walking, or taking a shower, without pausing to catch their breath or resting. This extreme shortness of breath is caused when air becomes trapped in parts of the lung that are damaged by the disease. This trapped air causes the damaged areas of the lungs to get larger which puts pressure on the diaphragm and makes breathing difficult.
The valves are typically placed in patients only when the fissures or separations between the lobes of the lungs are not fused together; however, sometimes, even if a CT scan suggests that the fissures are not fused, they may be found to be fused during the procedure. In such cases, the surgeons at JFK have successfully used robotic technology to divide the fissures and place the valves.
More on the Zephyr Valves
The Zephyr® Valve was fast-tracked through the FDA’s “Breakthrough Device” designation. As part of the supporting evidence for the FDA premarket approval, four randomized controlled clinical trials, including the US approval study, LIBERATE was conducted. Data from the study showed that implantation of the Zephyr Valves successfully reduced shortness of breath while improving lung function, exercise capacity, and quality of life.1 These benefits lasted at least one-year post-treatment for patients with severe emphysema.
Since 2007, more than 25,000 patients have been treated with The Zephyr Valve worldwide. The Zephyr Valve treatment is included in severe COPD and emphysema treatment recommendations issued by leading health organizations worldwide, including the UK’s National Institute for Health and Care Excellent (NICE) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) which gives endobronchial valves a level ‘A’ evidence rating, the highest rating possible.
For more information visit https://uspatients.pulmonx.com